<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:58:37 -0700</creation_date>
  <update_date>2013-01-15 18:58:37 -0700</update_date>
  <accession>HMDBP01681</accession>
  <secondary_accessions>
    <accession>7018</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>Nuclear receptor subfamily 3 group C member 3</synonym>
    <synonym>PR</synonym>
  </synonyms>
  <gene_name>PGR</gene_name>
  <general_function>Involved in sequence-specific DNA binding transcription factor activity</general_function>
  <specific_function>Isoform A is inactive in stimulating c-Src/MAPK signaling on hormone stimulation</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB01939</accession>
      <name>Medroxyprogesterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01830</accession>
      <name>Progesterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14439</accession>
      <name>Etonogestrel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14449</accession>
      <name>Desogestrel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14495</accession>
      <name>Megestrol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14511</accession>
      <name>Levonorgestrel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14522</accession>
      <name>Dydrogesterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14726</accession>
      <name>Fluticasone Propionate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14855</accession>
      <name>Norethindrone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14961</accession>
      <name>Ethynodiol Diacetate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14972</accession>
      <name>Mifepristone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15092</accession>
      <name>Norgestimate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15467</accession>
      <name>Drospirenone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15500</accession>
      <name>Allylestrenol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15658</accession>
      <name>Norelgestromin</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>sequence-specific dna binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transition metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>zinc ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>lipid binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>steroid binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleic acid binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>dna binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ligand-dependent nuclear receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>steroid hormone receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>sequence-specific dna binding transcription factor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>biological regulation</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of biological process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of macromolecule metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of gene expression</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of transcription</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of transcription, dna-dependent</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>organelle</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane-bounded organelle</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intracellular membrane-bounded organelle</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>nucleus</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Isoform A:Nucleus</subcellular_location>
    <subcellular_location>Cytoplasm</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:1</chromosome_location>
    <locus>11q22-q23</locus>
    <gene_sequence>&gt;2802 bp
ATGACTGAGCTGAAGGCAAAGGGTCCCCGGGCTCCCCACGTGGCGGGCGGCCCGCCCTCC
CCCGAGGTCGGATCCCCACTGCTGTGTCGCCCAGCCGCAGGTCCGTTCCCGGGGAGCCAG
ACCTCGGACACCTTGCCTGAAGTTTCGGCCATACCTATCTCCCTGGACGGGCTACTCTTC
CCTCGGCCCTGCCAGGGACAGGACCCCTCCGACGAAAAGACGCAGGACCAGCAGTCGCTG
TCGGACGTGGAGGGCGCATATTCCAGAGCTGAAGCTACAAGGGGTGCTGGAGGCAGCAGT
TCTAGTCCCCCAGAAAAGGACAGCGGACTGCTGGACAGTGTCTTGGACACTCTGTTGGCG
CCCTCAGGTCCCGGGCAGAGCCAACCCAGCCCTCCCGCCTGCGAGGTCACCAGCTCTTGG
TGCCTGTTTGGCCCCGAACTTCCCGAAGATCCACCGGCTGCCCCCGCCACCCAGCGGGTG
TTGTCCCCGCTCATGAGCCGGTCCGGGTGCAAGGTTGGAGACAGCTCCGGGACGGCAGCT
GCCCATAAAGTGCTGCCCCGGGGCCTGTCACCAGCCCGGCAGCTGCTGCTCCCGGCCTCT
GAGAGCCCTCACTGGTCCGGGGCCCCAGTGAAGCCGTCTCCGCAGGCCGCTGCGGTGGAG
GTTGAGGAGGAGGATAGCTCTGAGTCCGAGGAGTCTGCGGGTCCGCTTCTGAAGGGCAAA
CCTCGGGCTCTGGGTGGCGCGGCGGCTGGAGGAGGAGCCGCGGCTTGTCCGCCGGGGGCG
GCAGCAGGAGGCGTCGCCCTGGTCCCCAAGGAAGATTCCCGCTTCTCAGCGCCCAGGGTC
GCCCTGGTGGAGCAGGACGCGCCGATGGCGCCCGGGCGCTCCCCGCTGGCCACCACGGTG
ATGGATTTCATCCACGTGCCTATCCTGCCTCTCAATCACGCCTTATTGGCAGCCCGCACT
CGGCAGCTGCTGGAAGACGAAAGTTACGACGGCGGGGCCGGGGCTGCCAGCGCCTTTGCC
CCGCCGCGGACTTCACCCTGTGCCTCGTCCACCCCGGTCGCTGTAGGCGACTTCCCCGAC
TGCGCGTACCCGCCCGACGCCGAGCCCAAGGACGACGCGTACCCTCTCTATAGCGACTTC
CAGCCGCCCGCTCTAAAGATAAAGGAGGAGGAGGAAGGCGCGGAGGCCTCCGCGCGCTCC
CCGCGTTCCTACCTTGTGGCCGGTGCCAACCCCGCAGCCTTCCCGGATTTCCCGTTGGGG
CCACCGCCCCCGCTGCCGCCGCGAGCGACCCCATCCAGACCCGGGGAAGCGGCGGTGACG
GCCGCACCCGCCAGTGCCTCAGTCTCGTCTGCGTCCTCCTCGGGGTCGACCCTGGAGTGC
ATCCTGTACAAAGCGGAGGGCGCGCCGCCCCAGCAGGGCCCGTTCGCGCCGCCGCCCTGC
AAGGCGCCGGGCGCGAGCGGCTGCCTGCTCCCGCGGGACGGCCTGCCCTCCACCTCCGCC
TCTGCCGCCGCCGCCGGGGCGGCCCCCGCGCTCTACCCTGCACTCGGCCTCAACGGGCTC
CCGCAGCTCGGCTACCAGGCCGCCGTGCTCAAGGAGGGCCTGCCGCAGGTCTACCCGCCC
TATCTCAACTACCTGAGGCCGGATTCAGAAGCCAGCCAGAGCCCACAATACAGCTTCGAG
TCATTACCTCAGAAGATTTGTTTAATCTGTGGGGATGAAGCATCAGGCTGTCATTATGGT
GTCCTTACCTGTGGGAGCTGTAAGGTCTTCTTTAAGAGGGCAATGGAAGGGCAGCACAAC
TACTTATGTGCTGGAAGAAATGACTGCATCGTTGATAAAATCCGCAGAAAAAACTGCCCA
GCATGTCGCCTTAGAAAGTGCTGTCAGGCTGGCATGGTCCTTGGAGGTCGAAAATTTAAA
AAGTTCAATAAAGTCAGAGTTGTGAGAGCACTGGATGCTGTTGCTCTCCCACAGCCATTG
GGCGTTCCAAATGAAAGCCAAGCCCTAAGCCAGAGATTCACTTTTTCACCAGGTCAAGAC
ATACAGTTGATTCCACCACTGATCAACCTGTTAATGAGCATTGAACCAGATGTGATCTAT
GCAGGACATGACAACACAAAACCTGACACCTCCAGTTCTTTGCTGACAAGTCTTAATCAA
CTAGGCGAGAGGCAACTTCTTTCAGTAGTCAAGTGGTCTAAATCATTGCCAGGTTTTCGA
AACTTACATATTGATGACCAGATAACTCTCATTCAGTATTCTTGGATGAGCTTAATGGTG
TTTGGTCTAGGATGGAGATCCTACAAACATGTCAGTGGGCAGATGCTGTATTTTGCACCT
GATCTAATACTAAATGAACAGCGGATGAAAGAATCATCATTCTATTCATTATGCCTTACC
ATGTGGCAGATCCCACAGGAGTTTGTCAAGCTTCAAGTTAGCCAAGAAGAGTTCCTCTGT
ATGAAAGTATTGTTACTTCTTAATACAATTCCTTTGGAAGGGCTACGAAGTCAAACCCAG
TTTGAGGAGATGAGGTCAAGCTACATTAGAGAGCTCATCAAGGCAATTGGTTTGAGGCAA
AAAGGAGTTGTGTCGAGCTCACAGCGTTTCTATCAACTTACAAAACTTCTTGATAACTTG
CATGATCTTGTCAAACAGCTTCATCTGTACTGCTTGAATACATTTATCCAGTCCCGGGCA
CTGAGTGTTGAATTTCCAGAAATGATGTCTGAAGTTATTGCTGCACAATTACCCAAGATA
TTGGCAGGGATGGTGAAACCCCTTCTCTTTCATAAAAAGTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>933</residue_number>
    <molecular_weight>98980.0</molecular_weight>
    <theoretical_pi>6.45</theoretical_pi>
    <pfams>
      <pfam>
        <name>Hormone_recep</name>
        <pfam_id>PF00104</pfam_id>
      </pfam>
      <pfam>
        <name>Prog_receptor</name>
        <pfam_id>PF02161</pfam_id>
      </pfam>
      <pfam>
        <name>zf-C4</name>
        <pfam_id>PF00105</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>None</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Progesterone receptor
MTELKAKGPRAPHVAGGPPSPEVGSPLLCRPAAGPFPGSQTSDTLPEVSAIPISLDGLLF
PRPCQGQDPSDEKTQDQQSLSDVEGAYSRAEATRGAGGSSSSPPEKDSGLLDSVLDTLLA
PSGPGQSQPSPPACEVTSSWCLFGPELPEDPPAAPATQRVLSPLMSRSGCKVGDSSGTAA
AHKVLPRGLSPARQLLLPASESPHWSGAPVKPSPQAAAVEVEEEDGSESEESAGPLLKGK
PRALGGAAAGGGAAAVPPGAAAGGVALVPKEDSRFSAPRVALVEQDAPMAPGRSPLATTV
MDFIHVPILPLNHALLAARTRQLLEDESYDGGAGAASAFAPPRSSPCASSTPVAVGDFPD
CAYPPDAEPKDDAYPLYSDFQPPALKIKEEEEGAEASARSPRSYLVAGANPAAFPDFPLG
PPPPLPPRATPSRPGEAAVTAAPASASVSSASSSGSTLECILYKAEGAPPQQGPFAPPPC
KAPGASGCLLPRDGLPSTSASAAAAGAAPALYPALGLNGLPQLGYQAAVLKEGLPQVYPP
YLNYLRPDSEASQSPQYSFESLPQKICLICGDEASGCHYGVLTCGSCKVFFKRAMEGQHN
YLCAGRNDCIVDKIRRKNCPACRLRKCCQAGMVLGGRKFKKFNKVRVVRALDAVALPQPV
GVPNESQALSQRFTFSPGQDIQLIPPLINLLMSIEPDVIYAGHDNTKPDTSSSLLTSLNQ
LGERQLLSVVKWSKSLPGFRNLHIDDQITLIQYSWMSLMVFGLGWRSYKHVSGQMLYFAP
DLILNEQRMKESSFYSLCLTMWQIPQEFVKLQVSQEEFLCMKVLLLLNTIPLEGLRSQTQ
FEEMRSSYIRELIKAIGLRQKGVVSSSQRFYQLTKLLDNLHDLVKQLHLYCLNTFIQSRA
LSVEFPEMMSEVIAAQLPKILAGMVKPLLFHKK</protein_sequence>
  </protein_properties>
  <genbank_protein_id>35652</genbank_protein_id>
  <uniprot_id>P06401</uniprot_id>
  <uniprot_name>PRGR_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1SQN</pdb_id>
  </pdb_ids>
  <genbank_gene_id>X51730</genbank_gene_id>
  <genecard_id>PGR</genecard_id>
  <geneatlas_id>PGR</geneatlas_id>
  <hgnc_id>HGNC:8910</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P: Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990 May;9(5):1603-14.</reference_text>
      <pubmed_id>2328727</pubmed_id>
    </reference>
    <reference>
      <reference_text>Misrahi M, Atger M, d'Auriol L, Loosfelt H, Meriel C, Fridlansky F, Guiochon-Mantel A, Galibert F, Milgrom E: Complete amino acid sequence of the human progesterone receptor deduced from cloned cDNA. Biochem Biophys Res Commun. 1987 Mar 13;143(2):740-8.</reference_text>
      <pubmed_id>3551956</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chen C, Opazo JC, Erez O, Uddin M, Santolaya-Forgas J, Goodman M, Grossman LI, Romero R, Wildman DE: The human progesterone receptor shows evidence of adaptive evolution associated with its ability to act as a transcription factor. Mol Phylogenet Evol. 2008 May;47(2):637-49. Epub 2008 Feb 1.</reference_text>
      <pubmed_id>18375150</pubmed_id>
    </reference>
    <reference>
      <reference_text>Knotts TA, Orkiszewski RS, Cook RG, Edwards DP, Weigel NL: Identification of a phosphorylation site in the hinge region of the human progesterone receptor and additional amino-terminal phosphorylation sites. J Biol Chem. 2001 Mar 16;276(11):8475-83. Epub 2000 Dec 7.</reference_text>
      <pubmed_id>11110801</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhang Y, Beck CA, Poletti A, Edwards DP, Weigel NL: Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor. Mol Endocrinol. 1995 Aug;9(8):1029-40.</reference_text>
      <pubmed_id>7476977</pubmed_id>
    </reference>
    <reference>
      <reference_text>Beck CA, Zhang Y, Altmann M, Weigel NL, Edwards DP: Stoichiometry and site-specific phosphorylation of human progesterone receptor in native target cells and in the baculovirus expression system. J Biol Chem. 1996 Aug 9;271(32):19546-55.</reference_text>
      <pubmed_id>8702648</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhang Y, Beck CA, Poletti A, Clement JP 4th, Prendergast P, Yip TT, Hutchens TW, Edwards DP, Weigel NL: Phosphorylation of human progesterone receptor by cyclin-dependent kinase 2 on three sites that are authentic basal phosphorylation sites in vivo. Mol Endocrinol. 1997 Jun;11(6):823-32.</reference_text>
      <pubmed_id>9171245</pubmed_id>
    </reference>
    <reference>
      <reference_text>Clemm DL, Sherman L, Boonyaratanakornkit V, Schrader WT, Weigel NL, Edwards DP: Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. Mol Endocrinol. 2000 Jan;14(1):52-65.</reference_text>
      <pubmed_id>10628747</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lange CA, Shen T, Horwitz KB: Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1032-7.</reference_text>
      <pubmed_id>10655479</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hsiao PW, Fryer CJ, Trotter KW, Wang W, Archer TK: BAF60a mediates critical interactions between nuclear receptors and the BRG1 chromatin-remodeling complex for transactivation. Mol Cell Biol. 2003 Sep;23(17):6210-20.</reference_text>
      <pubmed_id>12917342</pubmed_id>
    </reference>
    <reference>
      <reference_text>Pierson-Mullany LK, Lange CA: Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol. 2004 Dec;24(24):10542-57.</reference_text>
      <pubmed_id>15572662</pubmed_id>
    </reference>
    <reference>
      <reference_text>Narayanan R, Edwards DP, Weigel NL: Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. Mol Cell Biol. 2005 Apr;25(8):2885-98.</reference_text>
      <pubmed_id>15798179</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chadli A, Graham JD, Abel MG, Jackson TA, Gordon DF, Wood WM, Felts SJ, Horwitz KB, Toft D: GCUNC-45 is a novel regulator for the progesterone receptor/hsp90 chaperoning pathway. Mol Cell Biol. 2006 Mar;26(5):1722-30.</reference_text>
      <pubmed_id>16478993</pubmed_id>
    </reference>
    <reference>
      <reference_text>Man JH, Li HY, Zhang PJ, Zhou T, He K, Pan X, Liang B, Li AL, Zhao J, Gong WL, Jin BF, Xia Q, Yu M, Shen BF, Zhang XM: PIAS3 induction of PRB sumoylation represses PRB transactivation by destabilizing its retention in the nucleus. Nucleic Acids Res. 2006;34(19):5552-66. Epub 2006 Oct 4.</reference_text>
      <pubmed_id>17020914</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhang PJ, Zhao J, Li HY, Man JH, He K, Zhou T, Pan X, Li AL, Gong WL, Jin BF, Xia Q, Yu M, Shen BF, Zhang XM: CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome. EMBO J. 2007 Apr 4;26(7):1831-42. Epub 2007 Mar 8.</reference_text>
      <pubmed_id>17347654</pubmed_id>
    </reference>
    <reference>
      <reference_text>Daniel AR, Faivre EJ, Lange CA: Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol Endocrinol. 2007 Dec;21(12):2890-906. Epub 2007 Aug 23.</reference_text>
      <pubmed_id>17717077</pubmed_id>
    </reference>
    <reference>
      <reference_text>Daniel AR, Qiu M, Faivre EJ, Ostrander JH, Skildum A, Lange CA: Linkage of progestin and epidermal growth factor signaling: phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth. Steroids. 2007 Feb;72(2):188-201. Epub 2006 Dec 14.</reference_text>
      <pubmed_id>17173941</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zahedi RP, Lewandrowski U, Wiesner J, Wortelkamp S, Moebius J, Schutz C, Walter U, Gambaryan S, Sickmann A: Phosphoproteome of resting human platelets.  J Proteome Res. 2008 Feb;7(2):526-34. Epub 2007 Dec 19.</reference_text>
      <pubmed_id>18088087</pubmed_id>
    </reference>
    <reference>
      <reference_text>Faivre EJ, Daniel AR, Hillard CJ, Lange CA: Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol Endocrinol. 2008 Apr;22(4):823-37. Epub 2008 Jan 17.</reference_text>
      <pubmed_id>18202149</pubmed_id>
    </reference>
    <reference>
      <reference_text>Williams SP, Sigler PB: Atomic structure of progesterone complexed with its receptor.  Nature. 1998 May 28;393(6683):392-6.</reference_text>
      <pubmed_id>9620806</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhang Z, Olland AM, Zhu Y, Cohen J, Berrodin T, Chippari S, Appavu C, Li S, Wilhem J, Chopra R, Fensome A, Zhang P, Wrobel J, Unwalla RJ, Lyttle CR, Winneker RC: Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget. J Biol Chem. 2005 Aug 5;280(31):28468-75. Epub 2005 Jun 3.</reference_text>
      <pubmed_id>15937332</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Madauss KP, Stewart EL, Williams SP: The evolution of progesterone receptor ligands.  Med Res Rev. 2007 May;27(3):374-400.</reference_text>
        <pubmed_id>17013809</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Gizard F, Robillard R, Gross B, Barbier O, Revillion F, Peyrat JP, Torpier G, Hum DW, Staels B: TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. Mol Cell Biol. 2006 Oct;26(20):7632-44.</reference_text>
        <pubmed_id>17015480</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Wu HB, Fabian S, Jenab S, Quinones-Jenab V: Progesterone receptors activation after acute cocaine administration.  Brain Res. 2006 Dec 18;1126(1):188-92. Epub 2006 Nov 15.</reference_text>
        <pubmed_id>17109827</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP: The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol. 2007 Feb;21(2):359-75. Epub 2006 Nov 30.</reference_text>
        <pubmed_id>17138644</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Tranguch S, Smith DF, Dey SK: Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation. Reprod Biomed Online. 2006 Nov;13(5):651-60.</reference_text>
        <pubmed_id>17169175</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Luconi M, Bonaccorsi L, Maggi M, Pecchioli P, Krausz C, Forti G, Baldi E: Identification and characterization of functional nongenomic progesterone receptors on human sperm membrane. J Clin Endocrinol Metab. 1998 Mar;83(3):877-85.</reference_text>
        <pubmed_id>9506743</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etonogestrel</name>
        <accession>HMDB14439</accession>
      </metabolite>
      <reference>
        <reference_text>Macpherson AM, Archer DF, Leslie S, Charnock-Jones DS, Makkink WK, Smith SK: The effect of etonogestrel on VEGF, oestrogen and progesterone receptor immunoreactivity and endothelial cell number in human endometrium. Hum Reprod. 1999 Dec;14(12):3080-7.</reference_text>
        <pubmed_id>10601100</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etonogestrel</name>
        <accession>HMDB14439</accession>
      </metabolite>
      <reference>
        <reference_text>Charnock-Jones DS, Macpherson AM, Archer DF, Leslie S, Makkink WK, Sharkey AM, Smith SK: The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium. Hum Reprod. 2000 Aug;15 Suppl 3:85-95.</reference_text>
        <pubmed_id>11041225</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etonogestrel</name>
        <accession>HMDB14439</accession>
      </metabolite>
      <reference>
        <reference_text>Sitruk-Ware R: Pharmacological profile of progestins.  Maturitas. 2004 Apr 15;47(4):277-83.</reference_text>
        <pubmed_id>15063480</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etonogestrel</name>
        <accession>HMDB14439</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desogestrel</name>
        <accession>HMDB14449</accession>
      </metabolite>
      <reference>
        <reference_text>Bergink EW, van Meel F, Turpijn EW, van der Vies J: Binding of progestagens to receptor proteins in MCF-7 cells.  J Steroid Biochem. 1983 Nov;19(5):1563-70.</reference_text>
        <pubmed_id>6645495</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desogestrel</name>
        <accession>HMDB14449</accession>
      </metabolite>
      <reference>
        <reference_text>Fuhrmann U, Slater EP, Fritzemeier KH: Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays. Contraception. 1995 Jan;51(1):45-52.</reference_text>
        <pubmed_id>7750284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desogestrel</name>
        <accession>HMDB14449</accession>
      </metabolite>
      <reference>
        <reference_text>Kloosterboer HJ, Vonk-Noordegraaf CA, Turpijn EW: Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception. 1988 Sep;38(3):325-32.</reference_text>
        <pubmed_id>3139361</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desogestrel</name>
        <accession>HMDB14449</accession>
      </metabolite>
      <reference>
        <reference_text>Macpherson AM, Archer DF, Leslie S, Charnock-Jones DS, Makkink WK, Smith SK: The effect of etonogestrel on VEGF, oestrogen and progesterone receptor immunoreactivity and endothelial cell number in human endometrium. Hum Reprod. 1999 Dec;14(12):3080-7.</reference_text>
        <pubmed_id>10601100</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desogestrel</name>
        <accession>HMDB14449</accession>
      </metabolite>
      <reference>
        <reference_text>Charnock-Jones DS, Macpherson AM, Archer DF, Leslie S, Makkink WK, Sharkey AM, Smith SK: The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium. Hum Reprod. 2000 Aug;15 Suppl 3:85-95.</reference_text>
        <pubmed_id>11041225</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desogestrel</name>
        <accession>HMDB14449</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Megestrol</name>
        <accession>HMDB14495</accession>
      </metabolite>
      <reference>
        <reference_text>Vadivelu S, Sharer L, Schulder M: Regression of multiple intracranial meningiomas after cessation of long-term progesterone agonist therapy. J Neurosurg. 2010 May;112(5):920-4.</reference_text>
        <pubmed_id>19731987</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Megestrol</name>
        <accession>HMDB14495</accession>
      </metabolite>
      <reference>
        <reference_text>Mokbel K: Focus on anastrozole and breast cancer.  Curr Med Res Opin. 2003;19(8):683-8.</reference_text>
        <pubmed_id>14687437</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Megestrol</name>
        <accession>HMDB14495</accession>
      </metabolite>
      <reference>
        <reference_text>Wentling GK, Sevin BU, Geiger XJ, Bridges MD: Benign metastasizing leiomyoma responsive to megestrol: case report and review of the literature. Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1213-7.</reference_text>
        <pubmed_id>16343217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Megestrol</name>
        <accession>HMDB14495</accession>
      </metabolite>
      <reference>
        <reference_text>Gruber T, Dare AO, Balos LL, Lele S, Fenstermaker RA: Multiple meningiomas arising during long-term therapy with the progesterone agonist megestrol acetate. Case report. J Neurosurg. 2004 Feb;100(2):328-31.</reference_text>
        <pubmed_id>15086241</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Megestrol</name>
        <accession>HMDB14495</accession>
      </metabolite>
      <reference>
        <reference_text>Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH: Classification and pharmacology of progestins.  Maturitas. 2008 Sep-Oct;61(1-2):171-80.</reference_text>
        <pubmed_id>19434889</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Megestrol</name>
        <accession>HMDB14495</accession>
      </metabolite>
      <reference>
        <reference_text>Wermers RA, Hurley DL, Kearns AE: Osteoporosis associated with megestrol acetate.  Mayo Clin Proc. 2004 Dec;79(12):1557-61.</reference_text>
        <pubmed_id>15595341</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Megestrol</name>
        <accession>HMDB14495</accession>
      </metabolite>
      <reference>
        <reference_text>Wiedemann K, Hirschmann M, Knaudt K, Rupprecht R, Seier FE, Holsboer F: Sleep endocrine effects of megestrol acetate in healthy men.  J Neuroendocrinol. 1998 Sep;10(9):719-27.</reference_text>
        <pubmed_id>9744490</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Megestrol</name>
        <accession>HMDB14495</accession>
      </metabolite>
      <reference>
        <reference_text>Lamberts SW, Uitterlinden P, Bons EG, Verleun T: Comparison of the actions of RU 38486 and megestrol acetate in the model of a transplantable adrenocorticotropin- and prolactin-secreting rat pituitary tumor. Cancer Res. 1985 Mar;45(3):1015-9.</reference_text>
        <pubmed_id>2982481</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Megestrol</name>
        <accession>HMDB14495</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonorgestrel</name>
        <accession>HMDB14511</accession>
      </metabolite>
      <reference>
        <reference_text>Maruo T, Ohara N, Matsuo H, Xu Q, Chen W, Sitruk-Ware R, Johansson ED: Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Contraception. 2007 Jun;75(6 Suppl):S99-103. Epub 2007 Mar 21.</reference_text>
        <pubmed_id>17531625</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonorgestrel</name>
        <accession>HMDB14511</accession>
      </metabolite>
      <reference>
        <reference_text>Mirkin S, Wong BC, Archer DF: Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertil Steril. 2005 Aug;84(2):485-91.</reference_text>
        <pubmed_id>16084894</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonorgestrel</name>
        <accession>HMDB14511</accession>
      </metabolite>
      <reference>
        <reference_text>Hompes PG, Mijatovic V: Endometriosis: the way forward.  Gynecol Endocrinol. 2007 Jan;23(1):5-12.</reference_text>
        <pubmed_id>17484506</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonorgestrel</name>
        <accession>HMDB14511</accession>
      </metabolite>
      <reference>
        <reference_text>Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, Rosenberg M, Higgins J: Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol. 2006 Nov;108(5):1089-97.</reference_text>
        <pubmed_id>17077229</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonorgestrel</name>
        <accession>HMDB14511</accession>
      </metabolite>
      <reference>
        <reference_text>Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winneker RC, Horwitz KB, Lyttle CR: Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol. 2005 Dec;97(4):328-41. Epub 2005 Sep 12.</reference_text>
        <pubmed_id>16157482</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonorgestrel</name>
        <accession>HMDB14511</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dydrogesterone</name>
        <accession>HMDB14522</accession>
      </metabolite>
      <reference>
        <reference_text>Blois SM, Joachim R, Kandil J, Margni R, Tometten M, Klapp BF, Arck PC: Depletion of CD8+ cells abolishes the pregnancy protective effect of progesterone substitution with dydrogesterone in mice by altering the Th1/Th2 cytokine profile. J Immunol. 2004 May 15;172(10):5893-9.</reference_text>
        <pubmed_id>15128769</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dydrogesterone</name>
        <accession>HMDB14522</accession>
      </metabolite>
      <reference>
        <reference_text>Tamaya T, Tsurusaki T, Ide N, Yamada T, Murakami T, Wada K, Fujimoto Z, Okada H: Nuclear translocation of progesterone receptor--progestogen complex in vitro.  Nihon Sanka Fujinka Gakkai Zasshi. 1983 Jan;35(1):77-82.</reference_text>
        <pubmed_id>6827166</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dydrogesterone</name>
        <accession>HMDB14522</accession>
      </metabolite>
      <reference>
        <reference_text>Raghupathy R, Al Mutawa E, Makhseed M, Azizieh F, Szekeres-Bartho J: Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOG. 2005 Aug;112(8):1096-101.</reference_text>
        <pubmed_id>16045524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dydrogesterone</name>
        <accession>HMDB14522</accession>
      </metabolite>
      <reference>
        <reference_text>Okada H: [Metabolism, structure and biological activity of sex steroids].  Nihon Naibunpi Gakkai Zasshi. 1993 Feb 20;69(2):67-79.</reference_text>
        <pubmed_id>8486204</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dydrogesterone</name>
        <accession>HMDB14522</accession>
      </metabolite>
      <reference>
        <reference_text>Tamaya T, Furuta N, Ohono Y, Ide N, Tsurusaki T, Okada H: Chromatin transcription by progesterone-receptor complex in rabbit uterus.  Endocrinol Jpn. 1979 Feb;26(1):117-22.</reference_text>
        <pubmed_id>436795</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dydrogesterone</name>
        <accession>HMDB14522</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluticasone Propionate</name>
        <accession>HMDB14726</accession>
      </metabolite>
      <reference>
        <reference_text>Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6.</reference_text>
        <pubmed_id>16507850</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluticasone Propionate</name>
        <accession>HMDB14726</accession>
      </metabolite>
      <reference>
        <reference_text>Austin RJ, Maschera B, Walker A, Fairbairn L, Meldrum E, Farrow SN, Uings IJ: Mometasone furoate is a less specific glucocorticoid than fluticasone propionate.  Eur Respir J. 2002 Dec;20(6):1386-92.</reference_text>
        <pubmed_id>12503693</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norethindrone</name>
        <accession>HMDB14855</accession>
      </metabolite>
      <reference>
        <reference_text>Mendoza-Rodriguez CA, Camacho-Arroyo I, Garcia GA, Cerbon MA: Variations of progesterone receptor and c-fos gene expression in the rat uterus after treatment with norethisterone and its A-ring reduced metabolites. Contraception. 1999 May;59(5):339-43.</reference_text>
        <pubmed_id>10494488</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norethindrone</name>
        <accession>HMDB14855</accession>
      </metabolite>
      <reference>
        <reference_text>Madauss KP, Deng SJ, Austin RJ, Lambert MH, McLay I, Pritchard J, Short SA, Stewart EL, Uings IJ, Williams SP: Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7.</reference_text>
        <pubmed_id>15189034</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norethindrone</name>
        <accession>HMDB14855</accession>
      </metabolite>
      <reference>
        <reference_text>Garcia-Becerra R, Cooney AJ, Borja-Cacho E, Lemus AE, Perez-Palacios G, Larrea F: Comparative evaluation of androgen and progesterone receptor transcription selectivity indices of 19-nortestosterone-derived progestins. J Steroid Biochem Mol Biol. 2004 Jun;91(1-2):21-7.</reference_text>
        <pubmed_id>15261304</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norethindrone</name>
        <accession>HMDB14855</accession>
      </metabolite>
      <reference>
        <reference_text>Mirkin S, Wong BC, Archer DF: Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertil Steril. 2005 Aug;84(2):485-91.</reference_text>
        <pubmed_id>16084894</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norethindrone</name>
        <accession>HMDB14855</accession>
      </metabolite>
      <reference>
        <reference_text>Pasapera AM, Cerbon MA, Castro I, Gutierrez R, Camacho-Arroyo I, Garcia GA, Perez-Palacios G: Norethisterone metabolites modulate the uteroglobin and progesterone receptor gene expression in prepubertal rabbits. Biol Reprod. 1995 Feb;52(2):426-32.</reference_text>
        <pubmed_id>7711211</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norethindrone</name>
        <accession>HMDB14855</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethynodiol Diacetate</name>
        <accession>HMDB14961</accession>
      </metabolite>
      <reference>
        <reference_text>Tamaya T, Nioka S, Furuta N, Shimura T, Takano N: Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84.</reference_text>
        <pubmed_id>858280</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethynodiol Diacetate</name>
        <accession>HMDB14961</accession>
      </metabolite>
      <reference>
        <reference_text>Briggs MH: Contraceptive steroid binding to the human uterine progesterone-receptor.  Curr Med Res Opin. 1975;3(2):95-8.</reference_text>
        <pubmed_id>166800</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethynodiol Diacetate</name>
        <accession>HMDB14961</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mifepristone</name>
        <accession>HMDB14972</accession>
      </metabolite>
      <reference>
        <reference_text>Greb RR, Kiesel L, Selbmann AK, Wehrmann M, Hodgen GD, Goodman AL, Wallwiener D: Disparate actions of mifepristone (RU 486) on glands and stroma in the primate endometrium. Hum Reprod. 1999 Jan;14(1):198-206.</reference_text>
        <pubmed_id>10374120</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mifepristone</name>
        <accession>HMDB14972</accession>
      </metabolite>
      <reference>
        <reference_text>Sun M, Zhu G, Zhou L: [Effect of mifepristone on the expression of progesterone receptor messenger RNA and protein in uterine leiomyomata]. Zhonghua Fu Chan Ke Za Zhi. 1998 Apr;33(4):227-31.</reference_text>
        <pubmed_id>10682471</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mifepristone</name>
        <accession>HMDB14972</accession>
      </metabolite>
      <reference>
        <reference_text>Hazra BG, Basu S, Pore VS, Joshi PL, Pal D, Chakrabarti P: Synthesis of 11beta-(4-dimethylaminophenyl)-17beta-hydroxy-17alpha- (3-methyl-1-butynyl)-4, 9-estradien-3-one and 11beta-(4-acetophenyl)- 17beta-hydroxy-17alpha-(3-methyl-1-butynyl)-4, 9-estradien-3-one: two new analogs of mifepristone (RU-486). Steroids. 2000 Mar;65(3):157-62.</reference_text>
        <pubmed_id>10699595</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mifepristone</name>
        <accession>HMDB14972</accession>
      </metabolite>
      <reference>
        <reference_text>Gao Y, Cheng L, Liu Y: [Failure of mifepristone induced interruption of pregnancy: point mutation at genetic codon 722 in human progesterone receptor gene]. Zhonghua Fu Chan Ke Za Zhi. 1998 Sep;33(9):549-52.</reference_text>
        <pubmed_id>10806733</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mifepristone</name>
        <accession>HMDB14972</accession>
      </metabolite>
      <reference>
        <reference_text>Jiang J, Wu R, Wang Z: [Effects of mifepristone on expression of estrogen receptor and progesterone receptor in cultured human eutopic and ectopic endometria]. Zhonghua Fu Chan Ke Za Zhi. 2001 Apr;36(4):218-21.</reference_text>
        <pubmed_id>11783365</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mifepristone</name>
        <accession>HMDB14972</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norgestimate</name>
        <accession>HMDB15092</accession>
      </metabolite>
      <reference>
        <reference_text>London RS, Chapdelaine A, Upmalis D, Olson W, Smith J: Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet Gynecol Scand Suppl. 1992;156:9-14.</reference_text>
        <pubmed_id>1324557</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norgestimate</name>
        <accession>HMDB15092</accession>
      </metabolite>
      <reference>
        <reference_text>Graziottin A: A review of transdermal hormonal contraception : focus on the ethinylestradiol/norelgestromin contraceptive patch. Treat Endocrinol. 2006;5(6):359-65.</reference_text>
        <pubmed_id>17107221</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norgestimate</name>
        <accession>HMDB15092</accession>
      </metabolite>
      <reference>
        <reference_text>Kuhnz W, Fritzemeier KH, Hegele-Hartung C, Krattenmacher R: Comparative progestational activity of norgestimate, levonorgestrel-oxime and levonorgestrel in the rat and binding of these compounds to the progesterone receptor. Contraception. 1995 Feb;51(2):131-9.</reference_text>
        <pubmed_id>7750291</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norgestimate</name>
        <accession>HMDB15092</accession>
      </metabolite>
      <reference>
        <reference_text>Juchem M, Pollow K, Elger W, Hoffmann G, Mobus V: Receptor binding of norgestimate--a new orally active synthetic progestational compound. Contraception. 1993 Mar;47(3):283-94.</reference_text>
        <pubmed_id>8384965</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norgestimate</name>
        <accession>HMDB15092</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Drospirenone</name>
        <accession>HMDB15467</accession>
      </metabolite>
      <reference>
        <reference_text>Krattenmacher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.  Contraception. 2000 Jul;62(1):29-38.</reference_text>
        <pubmed_id>11024226</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Drospirenone</name>
        <accession>HMDB15467</accession>
      </metabolite>
      <reference>
        <reference_text>Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winneker RC, Horwitz KB, Lyttle CR: Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol. 2005 Dec;97(4):328-41. Epub 2005 Sep 12.</reference_text>
        <pubmed_id>16157482</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Drospirenone</name>
        <accession>HMDB15467</accession>
      </metabolite>
      <reference>
        <reference_text>Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH: The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996 Oct;54(4):243-51.</reference_text>
        <pubmed_id>8922878</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Drospirenone</name>
        <accession>HMDB15467</accession>
      </metabolite>
      <reference>
        <reference_text>Arias-Loza PA, Hu K, Schafer A, Bauersachs J, Quaschning T, Galle J, Jazbutyte V, Neyses L, Ertl G, Fritzemeier KH, Hegele-Hartung C, Pelzer T: Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats. Hypertension. 2006 Nov;48(5):994-1001. Epub 2006 Sep 25.</reference_text>
        <pubmed_id>17000933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Drospirenone</name>
        <accession>HMDB15467</accession>
      </metabolite>
      <reference>
        <reference_text>Sitruk-Ware R: New progestagens for contraceptive use.  Hum Reprod Update. 2006 Mar-Apr;12(2):169-78. Epub 2005 Nov 16.</reference_text>
        <pubmed_id>16291771</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Drospirenone</name>
        <accession>HMDB15467</accession>
      </metabolite>
      <reference>
        <reference_text>Sitruk-Ware R: New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging. 2004;21(13):865-83.</reference_text>
        <pubmed_id>15493951</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allylestrenol</name>
        <accession>HMDB15500</accession>
      </metabolite>
      <reference>
        <reference_text>Madauss KP, Stewart EL, Williams SP: The evolution of progesterone receptor ligands.  Med Res Rev. 2007 May;27(3):374-400.</reference_text>
        <pubmed_id>17013809</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allylestrenol</name>
        <accession>HMDB15500</accession>
      </metabolite>
      <reference>
        <reference_text>Gizard F, Robillard R, Gross B, Barbier O, Revillion F, Peyrat JP, Torpier G, Hum DW, Staels B: TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. Mol Cell Biol. 2006 Oct;26(20):7632-44.</reference_text>
        <pubmed_id>17015480</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allylestrenol</name>
        <accession>HMDB15500</accession>
      </metabolite>
      <reference>
        <reference_text>Wu HB, Fabian S, Jenab S, Quinones-Jenab V: Progesterone receptors activation after acute cocaine administration.  Brain Res. 2006 Dec 18;1126(1):188-92. Epub 2006 Nov 15.</reference_text>
        <pubmed_id>17109827</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allylestrenol</name>
        <accession>HMDB15500</accession>
      </metabolite>
      <reference>
        <reference_text>Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP: The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol. 2007 Feb;21(2):359-75. Epub 2006 Nov 30.</reference_text>
        <pubmed_id>17138644</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allylestrenol</name>
        <accession>HMDB15500</accession>
      </metabolite>
      <reference>
        <reference_text>Tranguch S, Smith DF, Dey SK: Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation. Reprod Biomed Online. 2006 Nov;13(5):651-60.</reference_text>
        <pubmed_id>17169175</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allylestrenol</name>
        <accession>HMDB15500</accession>
      </metabolite>
      <reference>
        <reference_text>Bergink EW, Loonen PB, Kloosterboer HJ: Receptor binding of allylestrenol, a progestagen of the 19-nortestosterone series without androgenic properties. J Steroid Biochem. 1985 Aug;23(2):165-8.</reference_text>
        <pubmed_id>3928974</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norelgestromin</name>
        <accession>HMDB15658</accession>
      </metabolite>
      <reference>
        <reference_text>Henzl MR: Norgestimate. From the laboratory to three clinical indications.  J Reprod Med. 2001 Jul;46(7):647-61.</reference_text>
        <pubmed_id>11499185</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norelgestromin</name>
        <accession>HMDB15658</accession>
      </metabolite>
      <reference>
        <reference_text>Pasqualini JR: Breast cancer and steroid metabolizing enzymes: the role of progestogens.  Maturitas. 2009 Dec;65 Suppl 1:S17-21. Epub 2009 Dec 3.</reference_text>
        <pubmed_id>19962254</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norelgestromin</name>
        <accession>HMDB15658</accession>
      </metabolite>
      <reference>
        <reference_text>London RS, Chapdelaine A, Upmalis D, Olson W, Smith J: Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet Gynecol Scand Suppl. 1992;156:9-14.</reference_text>
        <pubmed_id>1324557</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norelgestromin</name>
        <accession>HMDB15658</accession>
      </metabolite>
      <reference>
        <reference_text>Graziottin A: A review of transdermal hormonal contraception : focus on the ethinylestradiol/norelgestromin contraceptive patch. Treat Endocrinol. 2006;5(6):359-65.</reference_text>
        <pubmed_id>17107221</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norelgestromin</name>
        <accession>HMDB15658</accession>
      </metabolite>
      <reference>
        <reference_text>Kuhnz W, Fritzemeier KH, Hegele-Hartung C, Krattenmacher R: Comparative progestational activity of norgestimate, levonorgestrel-oxime and levonorgestrel in the rat and binding of these compounds to the progesterone receptor. Contraception. 1995 Feb;51(2):131-9.</reference_text>
        <pubmed_id>7750291</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norelgestromin</name>
        <accession>HMDB15658</accession>
      </metabolite>
      <reference>
        <reference_text>Juchem M, Pollow K, Elger W, Hoffmann G, Mobus V: Receptor binding of norgestimate--a new orally active synthetic progestational compound. Contraception. 1993 Mar;47(3):283-94.</reference_text>
        <pubmed_id>8384965</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
